Earlier this month Infinity Pharmaceuticals presented updates on the clinical development and commercial strategy for duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, during its Research and Development (R&D) Day. The company also discussed its immuno-oncology candidate, IPI-549, a selective PI3K-gamma inhibitor for the treatment of solid tumors, along with a review of the agent’s data presented during the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference and plans to initiate a Phase I study on solid tumors. Infinity was also pleased to announce it has enrolled the 120th patient in DYNAMO, a Phase II study on patients with refractory indolent non-Hodgkin lymphoma (iNHL), and disclosed that topline data from the DYNAMO study should be available within Q3 of 2016.
“We are entering into an exciting time for Infinity,” stated Julian Adams, the company’s president, research and development. “During our R&D Day, we will provide a thorough review of our duvelisib program, including preclinical and clinical data that support our registration focused trials in iNHL and CLL, DYNAMO and DUO, respectively, and outline our clinical development strategy to further differentiate duvelisib. We are extremely pleased to have some of the top experts in leukemia, lymphoma and immuno-oncology to provide the physician’s perspective based on their knowledge and experience, and we also look forward to sharing the innovative science that led to IPI-549.”
Aside from product candidate updates, the company also officially revealed that it has appointed a new executive vice president. As of October 19, 2015, new EVP William Bertrand is working under Infinity’s chair, president and CEO, Adelene Perkins.
RELATED: Looking Back: 2015 International Blood Cancer Awareness Month Raises Awareness & Hope For An Eventual Cure
“Bill has tremendous experience along the entire biotechnology value chain from preclinical through commercialization as the first and only general counsel of MedImmune and most recently, as the chief operating officer and general manager of Salix prior to its acquisition by Valeant this summer,” stated Adelene Perkins, Infinity’s president and chief executive officer. “Bill will serve on Infinity’s senior executive leadership team and play an important role in helping us build the company and bring duvelisib to patients.”
“We look forward to sharing our vision for Infinity as well as providing an update on our development programs. With the recent completion of patient enrollment in DYNAMO, our ongoing duvelisib trials, the start of important new trials later this year, and the expansion of our pipeline with IPI-549, we are taking key steps toward our goal of delivering important new medicines to patients that could make a meaningful difference in their lives.”
The October 6, 2015, R&D presentation is currently archived in the company’s website under the Investors/Media section and will be available for the next 90 days.
